When mice bearing colorectal cancer xenografts were treated with cetuximab, the response rates mirrored those seen in clinical trials of cetuximab, and tumors bearing KRAS mutations were resistant to cetuximab, as are most KRAS-mutant colon cancers in human patients [14]. This evidence concerns the gene KRAS and malignant colon neoplasm.